This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Omnicell (OMCL) Up 27.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Omnicell (OMCL) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Omnicell (OMCL) steadily benefits from product introductions, strategic alliances and digital conversions.
Omnicell (OMCL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 4.48% and -1.35%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Omnicell Solid on Geographic Expansion Amid Stiff Competition
by Zacks Equity Research
Omnicell (OMCL) gains from expanding into new markets. Stiff rivalry is a concern.
Omnicell (OMCL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
Thermo Fisher (TMO) Down on Business Divestment Declaration
by Zacks Equity Research
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
CVS Health's PBM Pharmacy Platform to Ride on Walmart Deal
by Zacks Equity Research
Per the terms of the deal between CVS Health (CVS) and Walmart, the latter will continue to take part in the CVS Caremark PBM commercial and Managed Medicaid retail pharmacy networks.
Neogen Gains on Strong Genomic Arm Amid Stiff Competition
by Zacks Equity Research
Neogen's (NEOG) genomic business shows steady growth on acquisitions in Australia and Brazil. Stiff rivalry a cause of concern.
Why You Should Consider Buying Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.
Omnicell (OMCL) Rides on Innovation Despite Cost Concerns
by Zacks Equity Research
Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.
Allscripts Healthcare (MDRX) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Allscripts Healthcare (MDRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Near-Term Outlook for Medical Information Systems Industry
by Zacks Equity Research
The wave of digital transition is helping companies in the Zacks Medical Info Systems industry to create opportunities for investors.
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
by Zacks Equity Research
Omnicell (OMCL) continues to witness strong conversion wins for new XT series.
Omnicell (OMCL) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Omnicell (OMCL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
US Stocks Enjoy Highest Post-Midterm Gains Since 1982: 5 Picks
by Swarup Gupta
A large swathe of market watchers thinks that a gridlocked Congress will be beneficial for U.S. equity markets.
New Strong Buy Stocks for October 31st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.
Omnicell (OMCL) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 12.50% and 0.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omnicell Continues to Pursue Buyouts, Costs on the Rise
by Zacks Equity Research
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
Omnicell Patient Engagement Unit to Aid Medication Adherence
by Zacks Equity Research
Omnicell's (OMCL) revamped Patient Engagement platform likely to aid core Medication Adherence Unit; market looks promising.
Options Traders Expect Huge Moves in Omnicell (OMCL) Stock
by Zacks Equity Research
Omnicell (OMCL) needs investors to pay close attention to the stock based on moves in the options market lately.
Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.